Please assess the completion status of the following clinical trial:

Trial Title: A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria Inclusion criteria~1. Patients scheduled to undergo a primary, unilateral elective total knee replacement~2. Male or Female 20 years of age or order~3. Patients weighing at least 40 kg~4. Written informed consent prior to the start of study participation~Exclusion criteria Exclusion criteria~1. History of bleeding diathesis~2. Constitutional or acquired coagulation disorders that in the investigator's judgment puts the patient at excessive risk for bleeding~3. Major surgery or trauma (e.g. hip fracture) within the last 3 months~4. Recent unstable cardiovascular disease, such as uncontrolled hypertension at the time of enrollment (investigator's judgment) or history of myocardial infarction within the last 3 months~5. Any history of hemorrhagic stroke or any of the following intracranial pathologies: bleeding, neoplasm, AV (arteriovenous) malformation or aneurysm or recent bleeding history~6. Condition requiring anti-coagulant therapy~7. Elevated AST(Aspartate Aminotransferase) , ALT(Alanine Aminotransferase), or any history of clinically relevant liver disease~8. Patients with a history of clinically significant renal diseases or with elevated creatinine values

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabigatran etexilate 110 mg (Type: EXPERIMENTAL): Dabigatran etexilate 110 mg capsule, once a day, oral administration
- Dabigatran etexilate 150 mg (Type: EXPERIMENTAL): Dabigatran etexilate 150 mg capsule, once a day, oral administration
- Dabigatran etexilate 220 mg (Type: EXPERIMENTAL): Dabigatran etexilate 110 mg capsule, 2capsules, once a day, oral administration
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo capsule, once a day, oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).